Veracyte, Inc. (VCYT)

Market Cap	3.42B
Revenue (ttm)	495.14M
Net Income (ttm)	30.32M
Shares Out	79.05M
EPS (ttm)	0.38
PE Ratio	113.82
Forward PE	28.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	583,860
Open	41.73
Previous Close	41.69
Day's Range	41.23 - 43.60
52-Week Range	22.61 - 50.71
Beta	1.88
Analysts	Strong Buy
Price Target	46.00 (+6.24%)
Earnings Date	Feb 23, 2026

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 30, 2013
• Employees: 824
• Stock Exchange: NASDAQ
• Ticker Symbol: VCYT
• Website: https://www.veracyte.com

Analyst Summary

According to 8 analysts, the average rating for VCYT stock is "Strong Buy." The 12-month stock price target is $46.0, which is an increase of 6.24% from the latest price.

Price Target

$46.0

(6.24% upside)

Analyst Consensus: Strong Buy